Skip to main content

Table 5 Serum infliximab level and disease activity in three classes stratified on the basis of rheumatoid factor and anti-cyclic citrullinated peptide antibodies

From: High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

 

Low/low class (n = 53)

Middle class (n = 183)

High/high class (n = 71)

p Value

Serum infliximab level, μg/ml

 Week 2

13.9 (12.0, 15.7)

13.2 (10.2, 16.3)

12.0 (9.5, 14.2)

0.0028

 Week 6

7.6 (4.5, 10.8)

7.1 (2.5, 10.0)

5.0 (1.6, 8.2)

0.0072

 Week 10

7.7 (3.9, 10.5)

6.3 (2.0, 10.3)

3.8 (1.5, 7.9)

0.0040

 Week 14

1.5 (0.6, 2.1)

0.7 (<0.1, 2.0)

0.4 (<0.1, 1.1)

0.0014

 Week 14, < 0.1/≥ 0.1 to < 0.1/≥ 1.0

13%/25%/62%

33%/25%/42%

32%/38%/30%

0.0015

DAS28-CRP

 Week 2

3.89 (3.09, 4.51)

3.90 (3.24, 4.52)

4.01 (3.34, 4.79)

0.2770

 Week 6

3.32 (2.78, 4.16)

3.42 (2.67, 4.22)

3.68 (2.96, 4.36)

0.2381

 Week 10

3.19 (2.57, 3.77)

3.24 (2.55, 4.12)

3.48 (2.67, 4.20)

0.3612

 Week 14

3.17 (2.49, 3.69)

3.53 (2.63, 4.36)

3.82 (2.62, 4.97)

0.0764

 Week 14, REM/LDA/MDA/HDA

17%/15%/51%/17%

15%/12%/40%/33%

18%/10%/31%/41%

0.1455

  1. Abbreviations: DAS28-CRP Disease Activity Score in 28 joints based on C-reactive protein, HDA High disease activity, LDA Low disease activity without clinical remission, MDA Moderate disease activity, REM Clinical remission
  2. Data are median (interquartile range) or number of patients (%). Cutoff values for DAS28-CRP were as follows: REM < 2.3, LDA ≥ 2.3 to < 2.7, MDA ≥ 2.7 to ≤ 4.1, HDA > 4.1 [22]. The Kruskal-Wallis test was used to evaluate the differences among three classes